5052-95-9

Usage

Uses

Used in Pharmaceutical Industry:
1-Oxa-3,8-diazaspiro(4.5)decan 2-one is utilized as a precursor in the synthesis of bioactive compounds due to its structural similarity to existing pharmaceutical agents. Its unique spiro structure and oxygen-containing functional group contribute to its potential biological activity, making it a valuable compound for further research and drug development efforts.
Additionally, due to the lack of specific applications provided in the materials, the following potential uses are inferred based on the compound's properties and typical applications of similar compounds in the pharmaceutical field:
Used in Drug Development:
1-Oxa-3,8-diazaspiro(4.5)decan 2-one serves as a key intermediate in the development of new pharmaceuticals, leveraging its unique structural features to create novel therapeutic agents with potential applications in various medical conditions.
Used in Medicinal Chemistry Research:
As a compound of interest in medicinal chemistry, 1-Oxa-3,8-diazaspiro(4.5)decan 2-one is employed in research to explore its biological activity, understand its mechanism of action, and optimize its properties for specific therapeutic uses.

Upstream product

• 5053-14-5 8-Benzyl-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 23804-68-4 4-(aminomethyl)-1-benzyl-4-hydroxypiperidine 
• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 
• 169206-55-7 2-oxo-1-oxa-3,8-diazaspiro<4.5>decane-8-carboxylic acid tert-butyl ester 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 401811-97-0 4-ethoxycarbonylmethyl-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 502482-52-2 2-[4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]acetic acid 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 19867-34-6 N-benzyl-1-oxa-6-azaspiro[2,5]-octane 
• 177948-01-5 [[4-hydroxy-1-(phenylmethyl)-4-piperidinyl]methyl]carbamic acid 1,1-dimethylethyl ester 

Downstream Products

• 23855-97-2 8-(2-oxo-2-phenyl-ethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 5229-89-0 8-(2-benzo[1,3]dioxol-5-yl-ethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 6094-61-7 8-benzhydryl-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 77211-46-2 8-(carbobenzyloxy)-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 77211-59-7 8-[2-Hydroxy-3-(2-methoxy-phenoxy)-propyl]-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 77211-47-3 3-methyl-8-(carbobenzyloxy)-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 77211-48-4 3-Benzyl-2-oxo-1-oxa-3,8-diaza-spiro[4.5]decane-8-carboxylic acid benzyl ester 
• 79053-53-5 3-methyl-8-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one 
• 79053-04-6 (S)-3-methyl-8-<3-(2-methoxyphenoxy)-2-hydroxypropyl>-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 79053-52-4 (R)-3-methyl-8-<3-(2-methoxyphenoxy)-2-hydroxypropyl>-1-oxa-3,8-diazaspiro<4.5>decan-2-one 
• 23804-80-0 8-(4-amino-phenethyl)-1-oxa-3,8-diaza-spiro[4.5]decan-2-one 
• 1076863-60-9 C₂₅H₂₇N₅O₄ 
• 1538608-34-2 N-(2-amino-5-(4-methylthiophen-2-yl)phenyl)-6-(2-oxo-1-oxa-3,8-diazaspiro[4.5]decan-8-yl)nicotinamide 

Relevant academic research and scientific papers

Spirocyclic derivatives

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R1, R2, R3, R4, R5, R6, R9, R10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.

AUTOTAXIN INHIBITOR COMPOUNDS

Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity.

Delayed and prolonged histone hyperacetylation with a selective HDAC1/HDAC2 inhibitor

The identification and in vitro and in vivo characterization of a potent SHI-1:2 are described. Kinetic analysis indicated that biaryl inhibitors exhibit slow binding kinetics in isolated HDAC1 and HDAC2 preparations. Delayed histone hyperacetylation and

Design and synthesis of spirocyclic compounds as HCV replication inhibitors by targeting viral NS4B protein

Two novel series of spirocyclic piperidine analogs appended to a pyrazolo[1,5-a]pyridine core were designed, synthesized and evaluated for their anti-HCV activity. A series of piperidine ketals afforded dispiro 6p which showed excellent in vitro anti-HCV activities (EC50 of 1.5 nM and 1.2 nM against genotype 1a and 1b replicons, respectively). A series of piperidine oxazolidinones afforded 27c which showed EC50's of 10.9 nM and 6.1 nM against 1a and 1b replicons, respectively. Both compounds 6p and 27c bound directly to non-structural NS4B protein in vitro (IC50's = 10.2 and 30.4 nM, respectively) and exhibited reduced potency in replicons containing resistance mutations encoding changes in the NS4B protein.

Spirocyclic compounds

The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of n